Navigation Links
Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
Date:2/22/2013

NEW YORK, Feb. 22, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the Citigroup 2013 Global Healthcare Conference, being held February 25-27, 2013, in New York City.  Mr. Bentsur's presentation is scheduled to take place on Wednesday, February 27th, at 2:15 PM ET. 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.  Keryx is headquartered in New York City. 

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
8. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
9. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Genes ... for medications in select Florida and Texas doctors' offices and clinics. This breakthrough ... application of genetic testing recognizes the role genes play in determining an individual's ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman and ... in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency dental ... dentist fit into their patients’ busy lifestyles. Dental365 also gladly work with most ...
(Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ways ... alarm system installed. But unless there is a working deadbolt lock that is used ... Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use force ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... what is needed and will ultimately do significant harm to people with all ... everyone. , "While it leaves in place the Affordable Care Act (ACA) ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... (BCRA), their proposed healthcare bill to repeal and replace the Affordable Care Act ... bill would make significant cuts to Medicaid, a public health insurance program for ...
Breaking Medicine News(10 mins):